ID Source | ID |
---|---|
PubMed CID | 727030 |
CHEMBL ID | 1391342 |
CHEBI ID | 120751 |
SCHEMBL ID | 11436537 |
Synonym |
---|
1'h,3'h-spiro[cycloheptane-1,2'-perimidine] |
MLS000099315 , |
smr000071461 |
OPREA1_558715 |
CHEBI:120751 |
AKOS000646053 |
spiro[1,3-dihydroperimidine-2,1'-cycloheptane] |
HMS2387A06 |
spiro[2,3-dihydroperimidine-2,1'-cycloheptane] |
SCHEMBL11436537 |
bdbm40647 |
cid_727030 |
spiro[1,3-dihydroperimidine-2,1''-cycloheptane] |
CHEMBL1391342 |
Q27208888 |
Class | Description |
---|---|
naphthalenes | Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.2589 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 3.1623 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 3.1623 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 3.5481 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 12.5893 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
beta-amyloid peptide, A beta {N-terminal} [human, cerebrospinal fluid, conditioned medium of mixed-brain cell cultures, Peptide Partial, 33 aa] | Homo sapiens (human) | Potency | 2.2400 | 0.1500 | 4.5375 | 9.0200 | AID956 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624172 |
TDP1 protein | Homo sapiens (human) | Potency | 10.9523 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 8.3312 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID911 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 44.6684 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 3.1623 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 3.9811 | 0.0013 | 18.0743 | 39.8107 | AID926 |
alpha synuclein, partial | Homo sapiens (human) | Potency | 6.2864 | 0.1515 | 3.7637 | 6.2864 | AID937 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 4.4668 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0018 | 15.6638 | 39.8107 | AID894 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 1.4125 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 3.1623 | 0.6561 | 9.4520 | 25.1189 | AID927 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | Potency | 6.2864 | 0.1515 | 3.7637 | 6.2864 | AID937 |
Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | Potency | 6.2864 | 0.1515 | 3.7637 | 6.2864 | AID937 |
Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | Potency | 6.2864 | 0.1515 | 3.7637 | 6.2864 | AID937 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 3.1623 | 1.5849 | 13.0043 | 25.1189 | AID927 |
Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | Potency | 6.2864 | 0.1515 | 3.7637 | 6.2864 | AID937 |
Leukotriene B4 receptor 1 | Homo sapiens (human) | Potency | 13.5000 | 0.1800 | 3.9550 | 7.7300 | AID911 |
Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | Potency | 6.2864 | 0.1515 | 3.7637 | 6.2864 | AID937 |
Leukotriene B4 receptor 2 | Homo sapiens (human) | Potency | 13.5000 | 0.1800 | 3.9550 | 7.7300 | AID911 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 (µMol) | 53.2900 | 0.0375 | 18.6232 | 53.2000 | AID588524; AID588538 |
caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 (µMol) | 22.5000 | 0.0256 | 16.5070 | 52.8000 | AID588574 |
caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 22.5000 | 0.0256 | 20.3235 | 74.3000 | AID588574 |
nuclear receptor subfamily 4 group A member 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 78.3590 | 14.8560 | 25.3537 | 34.6240 | AID748 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |